

PATIENT INFORMATION

Referral Status: New Referral Updated Order Order Renewal

Patient Full Name: _____ DOB: _____ Phone: _____ Gender: M F Other

Email Address: _____ Address: _____ Weight (lbs/kg): _____ Height (in): _____

NKDA Allergies: _____ Existing prior authorization? Yes, (Send a copy) No (AIC will process)

Patient Status: New to Therapy Continuing Therapy Last Treatment Date: _____ Next Due Date: _____

Patient Preferred Location: _____

DIAGNOSIS & CLINICAL INFORMATION

ICD 10-Code & Description (Provide full completed code & description)

Primary Diagnosis must be checked:

Z00.6 Encounter for examination for normal comparison and control in clinical research program

Secondary Diagnosis:

G31.84 Mild Cognitive Impairment Due to Alzheimer's Disease

G30.0 Early Onset Alzheimer's Disease

G30.1 Late Onset Alzheimer's Disease

G30.8 Other Alzheimer's Disease

G30.9 Alzheimer's Disease unspecified

Other: _____

REQUIRED DOCUMENTATION: Please include insurance card (front & back), all patient demographics, history & physicals, medication lists, recent lab results (CBC, CMP, TB, Hep B panel-depending on medication) , signed prescription order and recent visit notes.

Confirm that these and the required lab orders have been sent to American Infusion Care and necessary parties.

PRESCRIPTION INFORMATION

Nursing: Provide nursing care per American Infusion Care - Specialty Infusions protocols, including reaction management and post-procedure observation

Pre-Medications

Acetaminophen (Tylenol) 500mg 650mg 1000mgPO
 Cetirizine (Zyrtec) 10mgPO
 Loratadine (Claritin) 10mgPO
 Diphenhydramine (Benadryl) 25mg 50mg PO IV
 Methylprednisolone (Solu-Medrol) 40mg 125mg IV
 Other: _____ Dose: _____ Route: _____

Lab Orders

Required: ApoE e4 Testing (if available)

Cognitive Assessment Score _____ (MMSE 20-28, CDR-GS 0.5 or 1)

MRI Within 1 Year Confirmed presence of amyloid pathology

CMS Registry Confirmation ALZH- _____ (Medicare and Medicare

Advantage only)

Patient has been provided ARIA Risk counseling

Other: _____

***Referring provider is responsible for obtaining an MRI prior to the 5th, 7th, and 14th infusions

Leqembi (lecanemab-irmb) (Select one):

10 mg/kg (____ mg) IV every 2 weeks
 10 mg/kg (____ mg) IV every 4 weeks (after 18 months of treatment only)
 Other: _____

Maintenance Dose: (can only be selected once patient has completed 18 months of standard dosing at the 2 week interval per the PI)

10mg/kg (____ mg) IV every 4 weeks

Other: _____

Post Treatment Observations: The patient is required to stay for 30 minutes following the first administration.

Refills: zero 6 months 12 months _____ (Prescription valid for one year, unless otherwise indicated)

Special Instructions: _____

PROVIDER INFORMATION

Provider Full Name: _____ Provider NPI #: _____ Specialty: _____

Practice Address: _____ City: _____ State: _____ Zip Code: _____

Contact Name: _____ Phone: _____ Fax: _____ Email: _____

Provider Name (Print)

Provider Signature

Date